DEF: PACS Group Addresses Restatement, Sets 2025 Annual Meeting Agenda

PACS Group, Inc. announces its 2025 Annual Meeting of Stockholders, outlining key proposals including director elections and executive compensation votes, while also addressing a prior financial restatement and related compensation clawbacks.

Summary

• The 2025 Annual Meeting of Stockholders will be held virtually on Friday, December 19, 2025, at 11:00 a.m. Mountain time.
• Holders of record of common stock as of November 10, 2025, are entitled to vote, with 156,615,444 shares outstanding.
• Key proposals include the election of Taylor Leavitt and Jacqueline Millard as Class I directors, ratification of Ernst & Young LLP as the independent auditor for fiscal year 2025, and advisory votes on executive compensation and its frequency.
• An independent internal investigation by the Audit Committee, prompted by a short-seller report, led to the restatement of condensed combined/consolidated financial statements for Q1 and Q2 2024.
• The restatement primarily impacted revenue and Adjusted EBITDA, reducing Q2 2024 Adjusted EBITDA by $37,411,000 from the previously reported $99,737,000 to $62,326,000.
• This resulted in $3,844,660 of erroneously awarded compensation under the 2024 Management Bonus Program.
• The company has recouped the full amount of erroneously awarded compensation from Messrs. Apt, Jergensen, Mitchell, and Sanford.
• As of the proxy statement date, $613,510 each in erroneously awarded compensation remains outstanding and unpaid by co-founders Messrs. Murray and Hancock.

Sentiment

Score: 3

Explanation: The significant financial restatement, the resulting clawback of executive compensation, and the underperformance relative to peers indicate substantial operational and governance issues. While the company is taking steps to address these, the unrecouped compensation from co-founders and the negative financial trends warrant a low sentiment score.

Positives

• The company maintains strong corporate governance standards, including a Code of Conduct and charters for its Audit, Compensation, and Nominating and Corporate Governance Committees.
• The executive compensation program emphasizes performance-based, at-risk compensation and equity awards to align executive interests with stockholders and promote long-term value creation.
• A clawback policy for erroneously awarded incentive compensation is in place and has been applied to recover funds from most executive officers.
• The Board recommends an annual advisory vote on executive compensation, demonstrating a commitment to regular dialogue with stockholders on governance matters.
• The Audit Committee conducted an independent internal investigation into third-party allegations, showing a proactive approach to addressing concerns.

Negatives

• Condensed combined/consolidated financial statements for Q1 and Q2 2024 required restatement due to identified errors, primarily impacting revenue and Adjusted EBITDA.
• Adjusted EBITDA for Q2 2024 was overstated by $37,411,000 prior to the restatement.
• Erroneously awarded compensation totaling $3,844,660 was paid under the 2024 Management Bonus Program due to the financial misstatements.
• As of the proxy statement date, $1,227,019 in erroneously awarded compensation remains unrecouped from co-founders Messrs. Murray and Hancock.
• One Form 4 reporting one transaction for director Jacqueline Millard was not filed on a timely basis for the year ended December 31, 2024.

Risks

• The staggered three-year terms for directors may delay or prevent a change in management or control of the company.
• Messrs. Murray and Hancock collectively beneficially own approximately 70% of the combined voting power, granting them significant control over director removal (with or without cause) and the ability to take stockholder action by written consent without a meeting.
• The company considers potential conflicts of interest with director candidates' other personal and professional pursuits during the selection process.
• The Audit Committee oversees the management of financial risks and information technology risks, including cybersecurity and data privacy risks.
• The Nominating and Corporate Governance Committee oversees risks associated with environmental and social matters.
• The Compensation Committee is responsible for overseeing the management of risks relating to the company's executive compensation plans and arrangements.

Future Outlook

The Board intends to consider stockholders' views regarding the frequency of future advisory votes on executive compensation. The next advisory say-on-pay vote is expected to occur at the 2026 Annual Meeting.

Management Comments

• "Whether or not you attend the Annual Meeting online, it is important that your shares be represented and voted at the Annual Meeting. Therefore, I urge you to promptly vote and submit your proxy by phone, via the Internet or by signing, dating and returning the enclosed proxy card in the enclosed envelope, which requires no postage if mailed in the United States." Jason Murray, Co-Founder, Chief Executive Officer and Chairman.
• "We believe that our compensation programs and policies for the year ended December 31, 2024 were an effective incentive for the achievement of our goals, aligned with stockholders interest and were worthy of stockholder support."

Industry Context

The company operates in the healthcare facilities and healthcare services industries, with a specific focus on the post-acute sector. Its executive compensation program is benchmarked against a peer group of companies operating in similar healthcare services, including skilled nursing facilities and other post-acute care providers, indicating a competitive landscape for talent and operational performance.

Comparison to Industry Standards

• The company's executive compensation program designs and pay levels are benchmarked against a peer group of 11 companies, including Acadia Healthcare Company, Inc., Brookdale Senior Living, LHC Group, Addus HomeCare Corporation, Chemed, National HealthCare, Amedisys, Encompass Health, Oak Street Health, ATI Physical Therapy, and Ensign Group.
• The company's Total Shareholder Return (TSR) from its IPO date (April 11, 2024) to December 31, 2024, was $57 (based on a $100 initial investment), significantly underperforming the Peer Group TSR of $116.06 over the same period. This suggests the company's stock performance has lagged behind its industry peers since becoming public.

Management Changes

Corporate Governance

Legal Proceedings

• An independent internal investigation was conducted by the Audit Committee into third-party allegations contained in a short-seller report published in November 2024.
• Legal and other costs of $9,727 thousand were incurred in 2024, associated with the Audit Committee's independent investigation and other ongoing investigations.

Related Party Transactions

• A Stockholders Agreement was entered into with Messrs. Murray and Hancock on April 10, 2024, affirming their board designation rights (collectively, four out of five directors) and voting agreement.
• A Registration Rights Agreement was entered into with Messrs. Murray and Hancock on April 10, 2024, providing them with customary demand and piggyback registration rights for their common stock.
• Messrs. Murray and Hancock and their respective spouses personally guarantee certain operating leases for facilities, and the company has agreed to indemnify them for any related damages or expenses.
• Mr. Murray and Mr. Hancock each pledged 9,500,000 shares of common stock as collateral for margin loans with UBS AG (terminated in November 2024), and the company executed pledge acknowledgments and consents related to these loans.
• The company entered into separate indemnification agreements with each of its directors and executive officers and purchased directors and officers liability insurance.

Stakeholder Impact

• Shareholders are directly impacted by the financial restatement, which may erode trust and affect stock valuation. The co-founders' significant voting power limits the influence of other shareholders.
• Executive officers faced compensation adjustments due to the restatement and clawback policy, impacting their earnings. Severance plans provide some financial security upon qualifying termination.
• Employees benefit from health and welfare plans, 401(k) retirement savings, and equity compensation for certain roles, aligning their interests with company performance.
• Creditors may view the financial restatement and unrecouped compensation as a concern regarding financial reporting reliability and management accountability.
• Regulatory bodies, particularly the SEC, are involved through the filing requirements, the internal investigation, and the restatement, indicating increased scrutiny on the company's compliance and financial disclosures.

Next Steps

• Stockholders will vote on director elections, auditor ratification, frequency of Say-on-Pay, and 2024 executive compensation at the Annual Meeting on December 19, 2025.
• The Audit Committee will consider the stockholder vote on the auditor appointment when appointing independent auditors for fiscal year 2026.
• The Board and Compensation Committee will consider stockholders' views on Say-on-Frequency and Say-on-Pay in making future executive compensation decisions.
• The company plans to announce preliminary voting results at the Annual Meeting and report final results in a Current Report on Form 8-K.
• The Compensation Committee will seek to recover the remaining erroneously awarded compensation from Messrs. Murray and Hancock.
• The next advisory say-on-pay vote is expected at the 2026 Annual Meeting.

Key Dates

Recommendation

The financial restatement for Q1 and Q2 2024, coupled with the significant clawback of executive compensation and the substantial underperformance of Total Shareholder Return relative to peers since the IPO, indicates material operational and governance weaknesses. The concentration of voting power with co-founders (70.4%) and the outstanding unrecouped compensation from them raise concerns about accountability and minority shareholder protection. While the company is addressing these issues, the immediate financial and governance concerns warrant a cautious stance, suggesting a 'sell' recommendation until there is clear evidence of sustained operational improvement, full resolution of compensation recoupment, and enhanced shareholder value creation.

Keywords

PACS Group, Proxy Statement, Annual Meeting, Corporate Governance, Executive Compensation, Financial Restatement, Clawback Policy, Director Election, Audit Firm Ratification, Say-on-Pay, Adjusted EBITDA, SEC Filing, Healthcare Services, Post-Acute Care